Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 1Melanoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 16Cyclophosphamide 9Nivolumab 7atezolizumab 6fludarabine 5Specimen Handling 5Magnetic Resonance Spectroscopy 5cabozantinib 4Trastuzumab 4budigalimab 3Ipilimumab 3Interleukin-2 3Cisplatin 3Capecitabine 3Albumin-Bound Paclitaxel 3spartalizumab 2sargramostim 2poly ICLC 2palbociclib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2X-Rays 2Sunitinib 2Paclitaxel 2Irinotecan 2Interleukin-12 2Immunoglobulin G 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Propranolol × Breast × Clear all
NCT02013492 2022-12-06

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
1 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Hepatocellular, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡